The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.
 
Noah M. Hahn
Honoraria - D3 Oncology Solutions
Speakers' Bureau - Medivation
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dendreon (Inst); Fluidigm (Inst); Genentech/Roche (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bionomics; Millennium
 
Joel Picus
Research Funding - Mirati Therapeutics (Inst)
 
Richard Martin Bambury
Leadership - Portable Medical Technology
Stock and Other Ownership Interests - Portable Medical Technology
 
Sumanta Kumar Pal
Honoraria - Medivation; Novartis
Consulting or Advisory Role - Aveo; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Lowell L. Hart
Research Funding - Mirati Therapeutics (Inst)
 
Petros Grivas
Consulting or Advisory Role - Myriad Genetics
Research Funding - Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Roche Pharma AG (Inst)
 
Matthew I. Milowsky
Research Funding - Astellas Pharma (Inst); BIND Therapeutics (Inst); Dendreon (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Mirati Therapeutics (Inst)
 
Ajjai Shivaram Alva
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Research Funding - BIND Biosciences; Bristol-Myers Squibb; Genentech; Novartis; Oncogenex
 
Guru Sonpavde
Consulting or Advisory Role - Bayer; Genentech; GlaxoSmithKline; Merck; Sanofi
Research Funding - Onyx (Inst)
 
Amir Mortazavi
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Elizabeth A. Guancial
No Relationships to Disclose
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Mary A. Collier
Employment - Mirati Therapeutics; Pfizer
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
 
James Christensen
Employment - Mirati Therapeutics; Pfizer
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Mirati Therapeutics; Pfizer
 
Isan Chen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Aragon Pharmaceuticals
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Travel, Accommodations, Expenses - Genentech/Roche